Header01-REBRAND_MENARINISILICONBIOSYSTEMS

 

Press Releases

12/10/2020

DETECT program studies validate clinical relevance of CTC HER2 phenotypes in metastatic breast cancer patients with HER2 negative primary tumor


Results presented at the 2020 San Antonio Breast Cancer Symposium confirm the relevance of screening for HER2+ CTCs from blood samples in patients with a HER2 negative primary tumor biopsy to optimize treatment strategy and patient outcome

continue →

Topics: CELLSEARCH, metastatic breast cancer, HER2, San Antonio Breast Cancer Symposium, CTC phenotyping

12/9/2020

New Global Pooled Analysis Supports Clinical Utility of Circulating Tumor Cell Count for Early Monitoring of Metastatic Breast Cancer


Robust pooled analysis demonstrating how CTC count may help to optimize treatment choices

continue →

Topics: CELLSEARCH, metastatic breast cancer, global pooled analysis, San Antonio Breast Cancer Symposium

11/9/2020

New Research Study Supports Clinical Utility of Circulating Tumor Cell Count for Metastatic Breast Cancer


First randomized clinical trial demonstrating that CTC count may help personalize treatment choices

continue →

Topics: CELLSEARCH, metastatic breast cancer, STIC

08/4/2020

Two Studies Presented at AACR Meeting Deepen Understanding Of Cancer Mechanisms

Researchers Use Menarini’s Liquid Biopsy Technology to Find Genetic Alterations in Cancer Cells that May Improve Prognosis and Treatment

continue →

Topics: CELLSEARCH, metastatic breast cancer, Multiple myeloma, HER2, AACR

06/10/2020

New ASCO Studies Offer Evidence for Use of Circulating Tumor Cells as a Prognostic Biomarker for Advanced Prostate and Breast Cancer

Results from prospective trials show a "clear prognostic value" for CTC counts

continue →

Topics: CTCs, CELLSEARCH, metastatic breast cancer, prostate cancer, ASCO

12/10/2019

New Menarini CELLSEARCH Studies to be Presented at San Antonio Breast Cancer Symposium

Northwestern University researchers use gold standard  liquid-biopsy technology to deepen understanding of metastatic breast cancer

continue →

Topics: Liquid biopsy, Precision Medicine, Circulating tumor cells, metastatic breast cancer, rare cells

05/30/2019

CellSearch Studies at ASCO Show Potential Predictive Role for Circulating Tumor Cells in Metastatic Breast Cancer

Liquid biopsy data reveals “intriguing” association between ESR1 mutations, HER2 alterations and prognosis

continue →

Topics: CELLSEARCH, Liquid biopsy, Precision Medicine, metastatic breast cancer

03/27/2019

New CellSearch Data To Be Presented at AACR Deepens Understanding of Metastatic Breast Cancer

Northwestern Researchers Use Gold-Standard Liquid Biopsy Technology to Identify Potential New Biomarker

continue →

Topics: deparray, CELLSEARCH, Liquid biopsy, Precision Medicine, metastatic breast cancer, lynphoma, CTC cluster, melanoma

11/29/2018

New Studies Using CELLSEARCH Circulating Tumor Cell Test to be Featured at San Antonio Breast Cancer Symposium

Research Adds to Growing Evidence of Clinical Utility of CTCs for the management of Metastatic Breast Cancer Patients

continue →

Topics: CTCs, CELLSEARCH, Liquid biopsy, Precision Medicine, metastatic breast cancer

05/30/2018

Circulating Tumor Cells to Help Stage Metastatic Breast Cancer, New Research To Be Featured at ASCO Annual Meeting

BOLOGNA, Italy and HUNTINGDON VALLEY, Pa., May 30, 2018 -- Menarini Silicon Biosystems announced today that a new study has found that using circulating tumor cells (CTCs), a form of liquid biopsy, holds promise as a key tool for developing a staging system that can have a significant impact in the treatment of metastatic breast cancer (MBC).

continue →

Topics: Circulating tumor cells, metastatic breast cancer